Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
The FDA’s single-trial doctrine shifted from proposal to practice last week, while Friday delivered two approvals—Vanda’s Bysanti for bipolar I disorder and schizophrenia, and CStone’s
A structural regime change at the FDA has codified “one pivotal trial” as the new approval default in a landmark New England Journal of Medicine
The FDA has issued a rare regulatory U-turn, reversing its refusal-to-file decision for Moderna’s mRNA flu vaccine after a high-stakes Type A meeting and setting
A classic “sell the news” reaction has cratered Ocular Therapeutix shares by 25% despite a successful Phase 3 superiority trial, proving that beating the endpoint
Roche has secured a definitive lead in autoimmune kidney disease with a Phase 3 win for Gazyva in primary membranous nephropathy, cementing its “deep B-cell
Last week delivered a regulatory reckoning that reshaped biotech valuation frameworks: the FDA rejected Disc Medicine’s bitopertin despite meeting its primary endpoint, issued a Refusal-to-File
BridgeBio’s “Switch” Data, FDA De-Risks HRT, Centivax Universal Flu — Oral Dwarfism Drug Beats Injectable Benchmarks, Pancreatic Cancer Device Approved, Seres & Ultragenyx Cut Staff
Merck has secured a pivotal first-mover advantage with the dual FDA approval of IV and subcutaneous Keytruda in platinum-resistant ovarian cancer, effectively building a defensive
The FDA’s high-profile refusal to review Moderna’s mRNA flu vaccine marks a regulatory pivot toward more stringent “gold-standard” comparator requirements, forcing a valuation reset for
Big Pharma is front-loading 2026 pipelines with AI-native discovery platforms and China-sourced clinical assets, as evidenced by nearly $11 billion in new deals from Takeda
